Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company that is developing therapies for patients suffering from serious diseases with a high unmet medical need. Its main focus is on developing voclosporin, an investigational drug, for the treatment of lupus nephritis and Dry Eye Syndrome. The company is headquartered in Victoria, British Columbia, and has a commercial hub in Rockville, MD. Aurinia focuses its development efforts globally.